Voyageur Pharmaceuticals Ltd. has achieved a significant milestone in developing pharmaceutical-grade barium sulfate from its natural Frances Creek resource, with independent laboratory testing confirming purity exceeding United States Pharmacopeia requirements and enabling progression to human clinical trials. The company's barium sulfate active pharmaceutical ingredient (API) demonstrated purity levels ranging from 98.1% to 99.4% across multiple samples, surpassing the USP monograph requirement of 97.5%, with an average grade of 98.8%. Testing conducted by SGS Laboratories in Mississauga, Ontario confirmed full USP compliance across all required parameters including identification, pH, loss on drying, and microbiological requirements.
The material's processing characteristics proved equally promising, with micronization trials at Sturtevant Inc. producing particle size distributions with d50 values of 1.1-1.9 µm and d90 values as low as 2.5 µm under optimal conditions. All micronized samples met USP particle size and performance criteria while exhibiting good flowability and 100% yield. The barium sulfate underwent controlled acid-wash procedures in a cGMP-compliant environment at SGS, with final processing and packaging completed under full Good Manufacturing Practices.
This development matters because it represents a potential shift in how medical imaging contrast media is sourced and manufactured in North America. Currently, pharmaceutical barium sulfate is almost entirely synthetically produced, which Voyageur management believes results in less effective imaging quality products. The company's natural resource from Frances Creek in British Columbia could provide higher quality, lower-cost alternatives while establishing domestic supply chain security. CEO Brent Willis stated that these results represent "a major de-risking milestone" and bring the company "significantly closer to a fully integrated, secure, and cost-effective North American supply chain for barium contrast media."
With these laboratory results, Voyageur advances to stage two of the Alberta Innovates AICE-Market Access Program, which includes manufacturing barium contrast agents for upcoming clinical trials designed by Chief Scientific Officer Dr. Iryna Saranchova in accordance with Health Canada standards. The clinical trial will compare Voyageur's contrasts with current commercially available standard-of-care options for gastrointestinal Computed Tomography and fluoroscopic imaging applications, evaluating investigational agents against both barium-based and iodinated oral contrasts. This comprehensive assessment approach ensures results are clinically meaningful and aligned with Health Canada, FDA, and international regulatory expectations.
The implications of successful trial outcomes extend beyond Voyageur's commercial interests to broader healthcare system benefits. Positive results could validate clinical performance of Voyageur's developing imaging contrasts, strengthen regulatory positioning, and accelerate progress toward market adoption. Full study completion is targeted for the fourth quarter of 2026, with results expected to enhance stakeholder confidence and support commercialization objectives. The clinical trial results will be pivotal for marketing and enhancing the company's FDA licensing applications, with the FDA process beginning in the first quarter of 2026.
By developing this domestic resource, Voyageur is building a fully integrated supply chain from quarry to finished contrast media, potentially reducing reliance on imported or synthetic materials while improving cost efficiency and supply reliability for hospitals and patients. The company has developed five barium contrast products that already have Health Canada licenses, positioning it to capitalize on successful trial outcomes. The Frances Creek project's prefeasibility and final feasibility study is expected by the fourth quarter of 2026, further defining the resource's commercial potential.
This advancement comes as Voyageur also announced corporate developments including the issuance of 378,651 Deferred Share Units to directors and a consultant, and the granting of 4,300,000 stock options to directors and officers. The company also announced a proposed issuance of securities for debt, subject to TSX Venture Exchange approval, involving units valued at $100,000 to be issued to an arm's length third party for financial advisory services. These corporate actions support the company's continued development efforts as it progresses toward clinical validation of its natural barium sulfate API.
